Metoclopramide
Brand names: Maxolon, Primperan
Metoclopramide is an antiemetic and prokinetic used for nausea and vomiting (including in migraine and some post-operative and chemotherapy settings).
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
A dopamine D2 antagonist with a prokinetic effect on the upper gastrointestinal tract that also acts centrally at the chemoreceptor trigger zone.
Prescribing in practice
- It can cause acute dystonic reactions and, with prolonged use, tardive dyskinesia — use the lowest dose for the shortest time (generally up to 5 days).
- The risk of extrapyramidal effects is higher in children, young adults and older people.
- Avoid in Parkinson's disease, in gastrointestinal obstruction/perforation and after recent GI surgery.
Monitoring
Watch for movement disorders and limit the duration of use.
Counselling the patient
- Report any abnormal movements, muscle stiffness or restlessness.
- It is for short-term use only.
Evidence & guidelines
An antiemetic/prokinetic restricted to short courses because of extrapyramidal risk (MHRA/EMA review).
Reference: NICE; EMA Metoclopramide Review 2014; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021